Acarbose Tablets 50mg for Glucose Response

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
AgelessRx, Ann Arbor, MI
Glucose Response+2 More
Acarbose Tablets 50mg - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

A Prospective Trial for Acarbose in Healthy Individuals Assessing Safety and Efficacy in Reducing Glucose Spikes After Carbohydrate Consumption.

Eligible Conditions

  • Glucose Response
  • Side Effects
  • Tolerance

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Glucose Response

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 120 minutes per phase, recorded on 4 separate occasions over 2 weeks.

Week 2
Monophasic glucose response
Week 2
Tolerability of Side Effect

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Glucose Response

Trial Design

2 Treatment Groups

Arm A
1 of 2
Arm B
1 of 2
Experimental Treatment

15 Total Participants · 2 Treatment Groups

Primary Treatment: Acarbose Tablets 50mg · No Placebo Group · Phase 4

Arm A
Drug
Experimental Group · 1 Intervention: Acarbose Tablets 50mg · Intervention Types: Drug
Arm B
Drug
Experimental Group · 1 Intervention: Acarbose Tablets 50mg · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 120 minutes per phase, recorded on 4 separate occasions over 2 weeks.
Closest Location: AgelessRx · Ann Arbor, MI
Photo of ann arbor 1Photo of ann arbor 2Photo of ann arbor 3
2021First Recorded Clinical Trial
1 TrialsResearching Glucose Response
2 CompletedClinical Trials

Who is running the clinical trial?

AgelessRxLead Sponsor
4 Previous Clinical Trials
2,790 Total Patients Enrolled

Eligibility Criteria

Age 18+ · null Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have been approved by the AgelessRx Medical team to take Acarbose.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.